title: Roundtable II: Cost concerns for rheumatoid arthritis treatment.
authors.forename: M
authors.initials: M
authors.lastname: Auslander
authors.forename: T
authors.initials: T
authors.lastname: Bresloff
authors.forename: D L
authors.initials: DL
authors.lastname: Clark
authors.forename: D
authors.initials: D
authors.lastname: Hillman
authors.forename: D L
authors.initials: DL
authors.lastname: Lewis
authors.forename: L
authors.initials: L
authors.lastname: Martinez
authors.forename: L
authors.initials: L
authors.lastname: Milgram
authors.forename: D
authors.initials: D
authors.lastname: Newcomer
authors.forename: T
authors.initials: T
authors.lastname: Nguyen
authors.forename: J
authors.initials: J
authors.lastname: Rae
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000191:economics* / Q000276:immunology / Q000628:therapy; D003362:Cost-Benefit Analysis; D016207:Cytokines / Q000191:economics / Q000627:therapeutic use; D003657:Decision Making; D016527:Drug Costs; D006297:Health Services Accessibility; D006801:Humans; D000069285:Infliximab; D019458:Insurance Coverage; D018579:Patient Selection; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab